CTX 130
Alternative Names: CTX-130Latest Information Update: 13 Jun 2024
At a glance
- Originator CRISPR Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I B-cell lymphoma; Renal cell carcinoma; T-cell lymphoma
Most Recent Events
- 05 Apr 2024 Pharmacodynamics, efficacy and adverse events data from the phase I COBALT-RCC trial in Renal cell carcinoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 28 Sep 2023 No recent reports of development identified for phase-I development in B-cell lymphoma (Second-line therapy or greater) in USA (IV, Infusion)
- 28 Sep 2023 No recent reports of development identified for phase-I development in T-cell-lymphoma(Second-line therapy or greater) in USA (IV, Infusion)